The Hippo pathway effectors TAZ and YAP are sequentially required in lung development.
H. Isago (Tokyo, Japan), A. Mitani (Tokyo, Japan), S. Kohno (Tokyo, Japan), H. Nagoshi (Tokyo, Japan), T. Ishimori (Tokyo, Japan), M. Saito (Tokyo, Japan), H. Tamiya (Tokyo, Japan), Y. Mikami (Tokyo, Japan), M. Horie (Tokyo, Japan), H. Urushiyama (Tokyo, Japan), T. Jo (Tokyo, Japan), G. Tanaka (Tokyo, Japan), R. Hamamoto (Tokyo, Japan), Y. Terasaki (Tokyo, Japan), T. Nagase (Tokyo, Japan)
Source: International Congress 2019 – Molecular and experimental paediatric lung disease
Session: Molecular and experimental paediatric lung disease
Session type: Oral Presentation
Number: 3604
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Isago (Tokyo, Japan), A. Mitani (Tokyo, Japan), S. Kohno (Tokyo, Japan), H. Nagoshi (Tokyo, Japan), T. Ishimori (Tokyo, Japan), M. Saito (Tokyo, Japan), H. Tamiya (Tokyo, Japan), Y. Mikami (Tokyo, Japan), M. Horie (Tokyo, Japan), H. Urushiyama (Tokyo, Japan), T. Jo (Tokyo, Japan), G. Tanaka (Tokyo, Japan), R. Hamamoto (Tokyo, Japan), Y. Terasaki (Tokyo, Japan), T. Nagase (Tokyo, Japan). The Hippo pathway effectors TAZ and YAP are sequentially required in lung development.. 3604
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: